Status:
RECRUITING
Implementing PrEP for Women Who Inject Drugs
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
HIV
Intravenous Substance Abuse
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Women who inject drugs are among the most vulnerable to acquiring HIV, but very few women who inject drugs are prescribed pre-exposure prophylaxis (PrEP) for HIV prevention largely due to barriers wit...
Detailed Description
Women who inject drugs (WWID) are among the most vulnerable to acquiring HIV due to the dual effects of both unsafe injecting and sexual practices. Pre-exposure prophylaxis (PrEP) is both effective an...
Eligibility Criteria
Inclusion
- To be included in the pilot test of Practice Facilitation, clinics must:
- Complete prior leadership and provider surveys
- Have 50 or more clinic visits with women who inject drugs in the past year
- Have 3 or more clinicians who provide primary and/or reproductive healthcare
- Have leadership willing to participate
Exclusion
- None
Key Trial Info
Start Date :
June 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05360849
Start Date
June 22 2021
End Date
December 31 2025
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania School of Nursing
Philadelphia, Pennsylvania, United States, 19104